Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10478487-B2

Patent

Publication Date

2019-11-19

Expiration Date

2036-01-15


Abstract

Compositions for prevention of Foot and Mouth Disease (FM D) are provided, comprising an antigen component in the amount equivalent to 0.5-20 μg FM D virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FM D persistence are also provided.

Core Innovation

Foot and Mouth Disease (FMD) is a highly contagious viral disease affecting cloven-hoofed animals with significant economic impacts globally. Existing killed-antigen FMD vaccines face challenges including high production costs in biological containment, difficulty in growing virulent virus strains, risk of virulent virus escape from manufacturing, and inability to differentiate infected from vaccinated animals by serological tests. Moreover, these vaccines lack cross-protection across serotypes, require strain matching, and historically have been ineffective in preventing virus persistence, where animals continue to shed virus beyond 28 days post-infection, potentially spreading disease.

The invention provides immunogenic compositions comprising a low antigen load of FMD virus (0.5-8 μg per dose) combined with a specific adjuvant formulation including an emulsion with an oily phase of at least 50% v/v, an immunostimulatory oligonucleotide (preferably CpG containing), and a polycationic polymer (such as DEAE dextran). Such compositions may also include a source of aluminum. The compositions can use genetically engineered FMD virus strains, including those with leader protein deletions and negative antigenic markers, enabling differentiation of infected from vaccinated animals (DIVA). These vaccines demonstrate protection at lower antigen amounts and have been shown to reduce or eliminate virus persistence.

Claims Coverage

This patent contains 22 inventive features covering methods of herd management using an immunogenic composition with specific antigen, adjuvant, and management parameters.

Use of low-dose FMD antigen with adjuvant composition for herd vaccination

The immunogenic composition comprises about 8-10 μg of FMD virus antigen, an emulsion containing oil, 75-200 μg of a CpG-containing immunostimulatory oligonucleotide per dose, and 75-200 mg of a polycationic carrier per dose, administered to each herd member.

Avoidance of slaughter of vaccinated animals upon suspected FMD exposure

Upon suspected contact with Foot-and-Mouth Disease infection, vaccinated herd members are not slaughtered following administration of the immunogenic composition.

Quarantine period management for vaccinated herds

Vaccinated herd members are quarantined for 0-30 days upon suspected FMD exposure after receiving the stated immunogenic composition.

Relocation of vaccinated herds beyond infected premises

Vaccinated herd members may be moved beyond infected premises upon suspected contact with FMD infection after administration of the immunogenic composition.

Preparation of FMD virus antigen by hollow fiber filtration

The FMD virus composition used in the immunogenic composition is prepared by hollow fiber filtration, providing antigen including structural and non-structural proteins.

Use of diethylaminoethyl (DEAE) Dextran as the polycationic polymer

The polycationic carrier component of the adjuvant formulation is diethylaminoethyl (DEAE) Dextran.

Immunostimulatory oligonucleotide comprising CpG motifs

The immunostimulatory oligonucleotide includes CpG-containing sequences, with specific sequences such as at least 15 contiguous nucleotides of SEQ ID NO: 8.

Inclusion of DIVA markers in FMD virus composition

The FMD virus composition comprises DIVA markers allowing differentiation of infected from vaccinated animals, including mutated 3B or 3D proteins.

Use of FMD virus Cruzeiro strain with heterologous capsid proteins

The virus composition includes FMD virus Cruzeiro strain optionally modified to contain heterologous capsid proteins from strains such as Asia1, Turkey06, O1Campos, C3Indaial, and A2001-Argentina.

Use of light mineral oil in oily phase of vaccine emulsion

The oily phase in the emulsion consists of light mineral oil comprising 50.01%-55% v/v of the composition.

The independent claims focus on herd management methods using an immunogenic composition with defined antigen amounts of FMD virus, an oil-containing emulsion adjuvant with a CpG immunostimulatory oligonucleotide and a polycationic carrier, providing protection against FMD while allowing modified herd management including reduced slaughter and quarantine. Additional inventive features specify the antigen preparation method, the nature of the polycationic polymer, inclusion of CpG oligonucleotides, DIVA markers, specific virus strains, and emulsion composition details.

Stated Advantages

Provides protection against Foot and Mouth Disease with a substantially lower antigen dose compared to existing vaccines.

Reduces or eliminates FMD virus persistence in vaccinated ruminants, thereby minimizing carrier state and virus shedding beyond 28 days post-infection.

Enables differentiation between infected and vaccinated animals (DIVA), facilitating improved disease monitoring and control.

Permits modified herd management practices such that vaccinated animals are not necessarily slaughtered upon suspected exposure.

Allows shortened or eliminated quarantine periods and movement of vaccinated animals beyond infected zones, thus improving outbreak control measures.

Improves vaccine safety and antigen quality by utilizing genetically engineered viruses and adjuvants including immunostimulatory oligonucleotides and polycationic carriers in specific oil emulsions.

Documented Applications

Use as an FMD vaccine composition for immunization of cloven-hoofed livestock including cattle, sheep, goats, and pigs.

Methods of preventing FMD infection in animals by administration of the described immunogenic compositions.

Reduction in frequency of persistent FMD infection and virus shedding in ruminants after vaccination.

Herd management protocols incorporating vaccination, wherein vaccinated animals are not slaughtered or are quarantined for reduced durations upon suspected FMD exposure.

Use of genetically engineered FMD virus antigens with DIVA markers for diagnostic differentiation of vaccinated versus infected animals.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.